

## Editorial Comment

# Catheter-Based Intervention: Pushing the Envelope\*

TONY M. CHOU, MD, FACC

San Francisco, California

The 20th anniversary of the first human application of percutaneous transluminal coronary angioplasty (PTCA) was celebrated in 1997 (1). During this brief lifetime, catheter-based revascularization has seen tremendous growth, expanding indications and dramatic technologic improvements. PTCA is now accepted as an effective therapy, with hundreds of thousands of procedures performed annually in the United States alone. However, timely, objective comparisons of PTCA, bypass surgery and medical therapy as options for patients with coronary artery disease have been limited. Although randomized trials have demonstrated that PTCA has a role in relieving anginal symptoms (2), is comparable to operation for multivessel disease in selected patients (3,4) and can serve to provide effective reperfusion in the setting of acute myocardial infarction (5-7), such important clinical data often reach publication when advancing technologies have made their relevance to modern practice unclear. Data on new devices are often from single-center, single-device reports that cannot agree on outcomes, such as "success" and "restenosis," making comparisons problematic. Thus, patient selection and appropriate technique application for percutaneous coronary revascularization remains a case by case challenge.

Registry data have been key elements in the field of interventional cardiology in the documentation of strategy and outcome. The National Heart, Lung, and Blood Institute (NHLBI) has sponsored three important multicenter data collection efforts: PTCA I (1977 to 1981, 3,000 patients); PTCA II (1985 to 1986, 2,431 patients); and the New Approaches to Coronary Intervention (NACI) registry (1990 to 1994, 4,389 patients). Patients selected for PTCA in the PTCA II versus PTCA I registry demonstrated a clear trend: increased age, higher likelihood of multivessel disease, poorer left ventricular function, higher rate of previous myocardial infarction and increased lesion complexity (8). Nevertheless, with the advances in balloon and angioplasty techniques, most notably the development of steerable guide wires and improvements in balloon catheter technology (the over the wire system,

lower balloon profiles, improved trackability, perfusion systems), PTCA results appeared to continue to maintain high acute success rates despite increasing lesion complexity and patient comorbidity. A recent comparison of PTCA data from women in the PTCA II registry with a 500-woman component of the NHLBI NACI registry from 1993 to 1994 confirmed the improving clinical success rates of PTCA despite the higher risk profile (9).

The PTCA registries were critical in establishing and validating the American College of Cardiology/American Heart Association (ACC/AHA) scoring system, which allowed systematic characterization of stenoses for catheter-based approaches (10,11). The limitations of balloon angioplasty were evident from these data, and the development of dozens of new technologies followed.

In this issue of the Journal, the comparison by King et al. (12) of the PTCA II and NACI registries continues the previous trends. Importantly, this comparative study found no superiority of the newer devices over PTCA when adjusted for an elective setting and the overall higher level of illness in the NACI cohort (12). Patient survival and freedom from target lesion revascularization by catheter or surgeon were the same in the two settings. It is a clinically important observation that the onset of new technologies has allowed for treatment of older patients with a higher rate of comorbidity, heart failure, previous myocardial infarction and previous bypass while maintaining a success rate similar to that of the PTCA II database (12).

How does the NACI registry translate to today's practice? Even in the few years since the NACI registry ended enrollment, the practice of interventional cardiology has evolved dramatically. The limitations of comparing registries from differing time frames make direct application to today's practice difficult. Although the precise data are not known, there has been a dramatic increase in the use of new single-device procedures, such as rotational atherectomy (11.5% of NACI registry patients examined), stenting (9.2%) and multiple-device procedures (6.6%). The use of directional coronary atherectomy (DCA) (30.6% of NACI patients examined) has gone down significantly since the long-term results of the randomized PTCA versus DCA trials were described (13,14).

The present study (12) examined only patients who underwent revascularization with new devices in the NACI registry as part of a elective or planned strategy. The entire NACI registry included >4,000 patients, many of whom presented with rescue stent procedures and acute myocardial infarction and were not included in the present analysis. Despite the more complex presentation of the entire NACI registry, high procedural and lesion success rates were maintained (15). Much of this success must be attributable to the advance of catheter technologies. The use of stents in rescue situations—a practice that has clearly changed the aggressiveness of balloon angioplasty use as well as new devices—was exclusionary. One would have to think that the use of stents in rescue situations would affect direct comparisons of the technology. Given that

\*Editorials published in *Journal of the American College of Cardiology* reflect the views of the authors and do not necessarily represent the views of *JACC* or the American College of Cardiology.

From the Adult Cardiac Catheterization Laboratories, Division of Cardiology and Cardiovascular Research Institute, University of California San Francisco, San Francisco, California.

Address for correspondence: Dr. Tony M. Chou, Adult Cardiac Catheterization Laboratories, Box 0124, University of California San Francisco, San Francisco, California 94143-0124. E-mail: chou@cardio.ucsf.edu.

**Abbreviations and Acronyms**

DCA	=	directional coronary atherectomy
NACI	=	New Approaches to Coronary Intervention
NHLBI	=	National Heart, Lung, and Blood Institute
PTCA	=	percutaneous transluminal coronary angioplasty

the advent of stenting allows more aggressive balloon sizing and dilation, the practice of PTCA during the NACI registry era is different from the use of PTCA during the PTCA II registry. This unavoidable confounder is further complicated by the relatively ubiquitous use of stenting today.

Many centers report rates of stenting in catheter-based intervention of 70% to 80%—a dramatic difference from the NACI cohort. Additionally, the NACI stent data were collected during an age of routine use of anticoagulation rather than antiplatelet therapy. During the early 1990s, the use of higher pressure stent deployment and intravascular ultrasound—techniques that appear to have an impact on overall success rates—were not common. Clearly, stenting today is safer and has a sustained improved outcome in combination with current techniques and antiplatelet therapy (16–19). With the release of newer stents with improved delivery characteristics, lower profiles and greater flexibility, the use of coronary stenting will increase as stent deployment approaches the ease of simple balloon dilation.

The NACI data predated the use of new adjuvant therapies that appear to be improving the acute and long-term results of catheter-based techniques. The focus on the platelet as a key agent in abrupt closure and restenosis (20,21), and the development of platelet glycoprotein IIb/IIIa inhibitors appears to be an area of great promise, as the experience with the monoclonal antibody fragment abciximab (22,23) and tirofiban (24) have borne out. The development of new antiplatelet agents will see our present-day management evolve. Local delivery of pharmacologic agents, including directed molecular therapies, will continue to be explored and may have a great impact (25–27). Catheter-based radiotherapy appears to improve short-term outcomes when used in conjunction with stenting in patients with restenosis (28).

The era of new devices in catheter-based revascularization has seen headway made in treating restenosis, diffuse disease, calcified lesions and reductions in abrupt closure. The lack of a clear benefit with the NACI database emphasizes the need for good clinical judgment in interventional decision making. This dynamic is vitally important to maintain the momentum that the “second-tier” devices have sustained since the approval of DCA in 1984. Procedures in complex lesions and high risk patients that could not have been feasible a decade ago are now considered routine. Unfortunately, randomized, controlled clinical trials evaluating these devices as they are released are logistically difficult, costly and obsolete by the time of completion because of rapid device evolution during

the trial period. It is here that registry data are most valuable. Although interventional cardiologists push the frontiers of what and whom it is possible to treat by means of catheter-based approaches with the use of new devices, it is clear that there is much work to be done to improve the long-term results.

**References**

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. *N Engl J Med* 1979;301:61–8.
2. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: Veterans Affairs ACME Investigators. *N Engl J Med* 1992;326:10–6.
3. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med* 1996;335:217–25.
4. King SR, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery: Emory Angioplasty versus Surgery Trial (EAST). *N Engl J Med* 1994;331:1044–50.
5. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfensperger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction: the Mayo Coronary Care Unit and Catheterization Laboratory Groups [see comments]. *N Engl J Med* 1993;328:685–91.
6. Grines CL, Booth DC, Nissen SE, et al. Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implications. *Am J Cardiol* 1990;65:1292–6.
7. Zijlstra F, De BM, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. *N Engl J Med* 1993;328:680–4.
8. Detre K, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981: the National Heart, Lung, and Blood Institute Registry. *N Engl J Med* 1988;318:265–70.
9. Jacobs AK, Kelsey SF, Yeh WL, et al. Documentation of decline in morbidity in women undergoing coronary angioplasty (a report from the 1993–94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). *Am J Cardiol* 1997;80:979–84.
10. Ellis SG, Cowley MJ, DiSciascio G, et al., for the Multivessel Angioplasty Prognosis Study Group. Determinants of 2-year outcome after coronary angioplasty in patients with multivessel disease on the basis of comprehensive preprocedural evaluation: implications for patient selection. *Circulation* 1991;83:1905–14.
11. Ellis SG, Vandormael MG, Cowley MJ, et al., for the Multivessel Angioplasty Prognosis Study Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. *Circulation* 1990;82:1193–202.
12. King SB, Yeh W, Holubkov R, et al. Balloon angioplasty versus new device intervention: clinical outcomes. A comparison of the NHLBI PTCA Registry and the NACI Registry. *J Am Coll Cardiol* 1997;31:558–66.
13. Elliott JM, Berdan LG, Holmes DR, et al. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). *Circulation* 1995;91:2158–66.
14. Holmes DJ, Topol EJ, Adelman AG, Cohen EA, Califf RM. Randomized trials of directional coronary atherectomy: implications for clinical practice and future investigation. *J Am Coll Cardiol* 1994;24:431–9.
15. Baim DS, Kent KM, King SR, et al. Evaluating new devices: acute (in-hospital) results from the New Approaches to Coronary Intervention Registry. *Circulation* 1994;89:471–81.
16. Schühlen H, Hadamitzky M, Walter H, Ulm K, Schomig A. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. *Circulation* 1997;95:2015–21.
17. Baim DS, Carrozza JJ. Stent thrombosis: closing in on the best preventive treatment [editorial]. *Circulation* 1997;95:1098–100.
18. Moussa I, Di MC, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary

- stenting without anticoagulation: frequency, predictors and clinical outcome. *J Am Coll Cardiol* 1997;29:6-12.
19. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996;334:1084-9.
  20. LeBreton H, Topol E, Plow EF. Evidence for a pivotal role of platelets in vascular reocclusion and restenosis [editorial]. *Cardiovasc Res* 1996;31:235-6.
  21. Le BH, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. *J Am Coll Cardiol* 1996;28:1643-51.
  22. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. *N Engl J Med* 1997;336:1689-96.
  23. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. *N Engl J Med* 1994;330:956-61.
  24. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. *Circulation* 1997;96:1445-53.
  25. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. *J Am Coll Cardiol* 1997;29:808-16.
  26. Tahlil O, Bami M, Feldman LJ, Branellec D, Steg PG. The Dispatch catheter as a delivery tool for arterial gene transfer. *Cardiovasc Res* 1997;33:181-7.
  27. Tomaru T, Fujimori Y, Morita T, et al. Local delivery of antithrombotic drug prevents restenosis after balloon angioplasty in atherosclerotic rabbit artery. *Jpn Circ J* 1996;60:981-92.
  28. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. *N Engl J Med* 1997;336:1697-703.